Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 251 Lymphoma 241 Precursor Cell Lymphoblastic Leukemia-Lymphoma 192 Leukemia 178 Lymphoma, Large B-Cell, Diffuse 167 Multiple Myeloma 166 Lymphoma, Non-Hodgkin 155 Leukemia, Lymphocytic, Chronic, B-Cell 146 Leukemia, Myeloid, Acute 136 Myelodysplastic Syndromes 116 Hodgkin Disease 115 Lymphoma, Follicular 113 Burkitt Lymphoma 108 Lymphoma, Mantle-Cell 104 Lymphoma, B-Cell, Marginal Zone 76 Lymphoma, Large-Cell, Immunoblastic 64 Neoplasms, Plasma Cell 59 Recurrence 58 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57 Myeloproliferative Disorders 53 Neoplasms 49 Leukemia, Myeloid, Chronic-Phase 49 Triple Negative Breast Neoplasms 47 Leukemia, Myeloid, Accelerated Phase 47 Melanoma 46 Leukemia, Myelomonocytic, Chronic 46 Dendritic Cell Sarcoma, Interdigitating 46 Waldenstrom Macroglobulinemia 42 Hematologic Neoplasms 41 Congenital Abnormalities 39

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Survival Without Progression × Cyclophosphamide × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡